Adding CBD to THC Actually Reduced Pain Relief in Rats with Inflammation

Oral THC dose-dependently decreased hyperalgesia and allodynia in a carrageenan inflammatory pain model, with stronger effects in females than males. The lowest THC dose (1 mg/kg) was actually pro-inflammatory in males. CBD alone did not affect pain sensitivity but had modest anti-inflammatory effects in males. When combined, CBD diminished THC antinociception (subadditive interaction), suggesting THC alone is superior to THC+CBD for acute inflammatory pain.

Male and female Sprague-Dawley rats (n=10-14 per sex/group) received oral pretreatment with vehicle, THC (1, 3, 10 mg/kg), CBD (10, 30, 100 mg/kg), or THC+CBD combinations 1 hour before carrageenan injection. Edema, thermal hyperalgesia, and mechanical allodynia measured at 1, 3, and 5 hours. Isobolographic and dose addition analyses assessed interaction type.

Many cannabis pain products contain both THC and CBD, assuming they work synergistically. This study challenges that assumption for inflammatory pain, suggesting pure THC formulations may be more effective.

The finding that CBD can antagonize THC pain relief contradicts the popular assumption that CBD always enhances or modulates THC effects beneficially. The sex difference in THC pain relief adds to growing evidence that cannabis-based pain treatments may need to be sex-specific.

Rat model of acute inflammatory pain may not translate to chronic pain conditions. Oral administration through gavage differs from human cannabis consumption. Only acute (pretreatment) effects studied. Specific THC:CBD ratios tested may not reflect commercial product ratios.